Health Canada has accepted for review the first portion of the rolling submission by Medicago for its plant-derived adjuvanted Covid-19 vaccine candidate.
GlaxoSmithKline (GSK) and Canadian biopharma company Medicago have launched a Phase III trial of their adjuvanted plant-derived COVID-19 vaccine candidate.
The vaccine containing a recombinant coronavirus virus-like particles (CoVLP) will be tested in three different doses and with two different adjuvants.